RegisterLogin

ABT-751

CAT: 0804-HY-13270-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13270-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer[1][2][3][4][5][6][7][8].
CAS Number
[141430-65-1]
Product Name Alternative
E7010
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ABT-751.html
Purity
99.40
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=CC=C(C=C1)S(=O)(NC2=C(N=CC=C2)NC3=CC=C(C=C3)O)=O
Molecular Formula
C18H17N3O4S
Molecular Weight
371.41
Precautions
H302, H315, H319, H335
References & Citations
[1]Huang SM et al., Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling., Nature. 2009 Oct 1;461 (7264) :614-20.|[2]Elizabeth Fox et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin Cancer Res February 15, 2008 14; 1111|[3]Aggarwal C, et al. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?, Cancer Biol Ther. 2012 Mar;13 (5) :247-63.|[4]Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C., Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma., J Vet Intern Med. 2012 Mar-Apr;26 (2) :349-54. doi: 10.1111/j.1939-1676.2012.00892.x. Epub 2012 Feb 28.|[5]Gaynon PS, Harned TM; for the Therapeutic Advances in Childhood LeukemiaLymphoma (TACL) Consortium.|[6]David Frost, et al. ABT-751, an oral antimitotic, shows additive and synergistic activity with docetaxel in preclinical models. Cancer Res 1 May 2007; 67 (9_Supplement) : 1426.|[7]Yoshimatsu K, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997;57 (15) :3208-3213.|[8]Morton CL, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs. 2007;25 (4) :285-295.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Related Products

CatalogName
HY-105425DWC 751
HY-D0996-01LDS-751
HY-W953635CRBN ligand-751
HY-120232-01ABT-963
HY-115133ABT-116
HY-19721-01ABT-639
HY-12195-01ABT-239
HY-50907-01ABT-737
HY-19483ABT-670
HY-15197-01ABT-046

Alternative Products

CatalogName
E1KS1165ABT-751
sc-361097ABT 751
MBS575371ABT-751 (E7010)
T88896-01ABT-751 hydrochloride
A10024-50ABT-751 50mg
A10024-100ABT-751 100mg
A10024-200ABT-751 200mg
A10024-10ABT-751 10mg
MBS130900-01ABT-751(E 7010)
MBS384113-01ABT-751 (E-7010)

Popular Products